Analyst Caitlin Cronin reaffirmed her Buy rating on Stryker, citing robust growth and clever business maneuvers. Stryker ...

Stryker boosts 2025 sales forecast after strong Q1 results, despite a $200M hit from tariffs on its global medical device ...